By Bernice Yeung, California Watch
Foster City drugmaker Gilead recently updated its application with the federal Food and Drug Administration for approval to market its HIV treatment medication Truvada as a HIV prevention pill.
If the FDA approves Truvada for preventive use, it “would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV through sex,” according to a company statement at the time of the filing last month.
Gilead’s application, however, has sparked debate among public health advocates who argue that the wide availability of the drug would discourage safe sex and would, in fact, increase the incidence of HIV. Continue reading